Nutex Health revenue leaps 82.4% to $875.3M, launches second buyback
Nutex Health’s total revenue surged 82.4% to $875.3 million in 2025 while adjusted EBITDA climbed 152.6% to $259.6 million, lifting net income to $70.8 million and diluted EPS to $10.48. The company generated $248.1 million in cash flow, saw hospital revenue jump 188% and authorized a second stock repurchase program.
1. Full Year 2025 Results
Nutex Health reported total revenue up 82.4% year-over-year to $875.3 million, driven by the hospital division’s $844.2 million revenue. Net income rose to $70.8 million with diluted EPS of $10.48 and adjusted EBITDA grew 152.6% to $259.6 million.
2. Hospital Division Growth
Hospital division revenue soared 188% to $844.2 million, with mature hospital revenue up 73.4%. Total visits increased 11.8% to 188,279, reflecting higher acuity claims and successful IDR arbitration outcomes.
3. Arbitration Strategy
The company submitted 50-60% of claims through Independent Dispute Resolution, prevailing in over 85% of determinations and collecting over 85% of awards, with arbitration costs at approximately 26% of related revenue.
4. Second Stock Repurchase Program
Nutex Health authorized a second stock repurchase program, signaling confidence in its cash generation following $248.1 million in operating cash flow, though program details remain pending disclosure.